TY - T1的附带表示“肺”前进nary embolism in cancer patients JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.04630-2020 VL - 58 IS - 1 SP - 2004630 AU - dos Santos Fernandes, Caio Julio Cesar AU - Couturaud, Francis Y1 - 2021/07/01 UR - //www.qdcxjkg.com/content/58/1/2004630.abstract N2 - The association between cancer and venous thromboembolism (VTE) has been well known since the 19th century. It was first described by Bouillaud in 1823 [1] but became widely recognised when Trousseau related his “phlegmatia alba dolens” in 1865 and, tragically, succumbed to the condition he described in 1866 [2]. Since then, the epidemiologic relevance of cancer-associated-thrombosis (CAT) has become quite relevant. It is believed that 20% of cancer patients present, during the evolution of the oncologic disease or its treatment, with an episode of VTE [3]. VTE is the second most common cause of death in cancer patients, after cancer progression [4]. Conversely, 20% of all VTE events are CAT [5] and cancer is the most prevalent cause of death in VTE patients [6]. CAT treatment is also not devoid of complexity and presents a challenge in itself. Cancer patients have a three-fold higher VTE recurrence rate than non-cancer patients, but they also present with a two-fold higher major bleeding rate [7].Incidental pulmonary embolism in cancer patients remains a challenge. Since its prognosis appears to differ from symptomatic PE, optimal anticoagulation strategies, including distinct anticoagulant dosage and duration, need to be better elucidated. https://bit.ly/3qnycpS ER -